Trials / Unknown
UnknownNCT04844554
Protocol of Assistance to Patients With Covid-19 Submitted to Treatment With HD-tDCS
Protocol of Assistance to Patients With Covid-19 Submitted to Treatment With HD-tDCS: Open Label, Randomized, Controlled Study
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Federal University of Paraíba · Academic / Other
- Sex
- All
- Age
- 20 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
COVID-19 has a variety of symptoms from asymptomatic respiratory dysfunction to death. Considering the pathophysiology of SARS-CoV-2 and its relationship with the neuroimmune system, response, autonomic balance, musculoskeletal and respiratory and neuropsychiatric symptoms presented by patients, the investigators highlight the potential use of non-invasive neuromodulation methods to assess the effectiveness of treating patients with COVID-19, as these techniques can be useful in the management of important clinical aspects in the functional recovery of individuals affected by the disease. The investigators intend to evaluate the effects of HD- tDCS to promote ventilatory weaning in patients admitted to the Intensive Care Unit (ICU) and to improve the respiratory performance of those hospitalized in nursing beds for treatment of COVID - 19.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Active HD-tDCS 3mA | This group will receive HD-tDCS 3mA intensitie. 0 sessions at ICU simultaneously to physical rehabilitation. The HD- tDCS will be started with a 30 s ramp-up to the desired intensity, which was maintained for 20 min. |
| OTHER | Sham HD-tDCS | This group will receive sham HD-tDCS. The intervention will be applied in 10 sessions at ICU simultaneously to physical rehabilitation. The HD- tDCS will be started with a 30 s ramp-up them turn off. |
Timeline
- Start date
- 2021-06-20
- Primary completion
- 2022-04-12
- Completion
- 2022-10-12
- First posted
- 2021-04-14
- Last updated
- 2022-03-10
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT04844554. Inclusion in this directory is not an endorsement.